Haematologic Malignancies
Research activity is centred on chronic myeloid leukaemia, with particular attention to CML-CP and CML-AP in patients carrying the T315I mutation.
- Chronic myeloid leukaemia
- CML-CP and CML-AP
- T315I mutation
The therapeutic focus includes patients with resistance, intolerance, or ineligibility to prior tyrosine kinase inhibitor options.
Targeted Oncology
The sponsor’s clinical interest extends to precision treatment approaches for BCR::ABL1-driven disease, with emphasis on molecularly defined patient populations.
- BCR::ABL1 molecular disease
- Targeted therapy
- Molecular response assessment
Research activity is aligned with monitoring deep haematologic response through BCR::ABL1 IS measurements.
Leukaemia Treatment Response
Clinical interest includes evaluation of treatment response in adult leukaemia patients with advanced or resistant disease features.
- Response evaluation
- Molecular remission
- Resistant disease
The funded research landscape is focused on outcomes relevant to molecular response in difficult-to-treat myeloid malignancies.
Tyrosine Kinase Inhibition
Another key area of interest is the use of tyrosine kinase inhibitor strategies in Philadelphia chromosome-positive leukaemia, particularly where standard options are limited.
- Tyrosine kinase inhibition
- Philadelphia chromosome-positive leukaemia
- Treatment-resistant disease
This includes investigation of patients who are intolerant or ineligible for established therapies.
